{"id":24552,"date":"2022-11-08T20:12:00","date_gmt":"2022-11-08T12:12:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24552"},"modified":"2025-01-31T20:15:16","modified_gmt":"2025-01-31T12:15:16","slug":"xellsmart-raises-rmb-200m-in-series-a1-round-for-stem-cell-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24552","title":{"rendered":"Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies"},"content":{"rendered":"\n<p>Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings, Founder H Fund, CE Innovation Capital, Frees Fund, Sequoia Capital China, and Next Capital. The proceeds will be used to fund a pre-clinical study for its iPS-derived cell therapy for neural system diseases, team expansion, and pilot production of its clinical-level iPS-derived cell therapies.<\/p>\n\n\n\n<p><strong>Company Profile and Pipeline<\/strong><br>Founded in 2021, Xellsmart is focused on developing scaled-up, low-cost stem-cell therapies for major diseases, including Parkinson&#8217;s disease (PD). The company has completed the construction of an 1,800-square-meter R&amp;D center and a large-scale manufacturing transformation plant. Xellsmart has also established key technology platforms, including iPS cell line reprogramming, iPSC gene editing, and differentiation of iPSCs into various subtypes of neural cells. Additionally, Xellsmart is a member of the CSDR\u2019s cell and gene therapy product regulatory research committee.<\/p>\n\n\n\n<p><strong>Future Development Plans<\/strong><br>The Series A1 funding will support Xellsmart&#8217;s pre-clinical study for its iPS-derived cell therapy, aimed at treating neural system diseases. The funds will also be used for team expansion and pilot production of its clinical-level therapies, positioning Xellsmart to advance its innovative treatments and improve accessibility for patients with neural diseases.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,20,2494],"class_list":["post-24552","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cell-therapy","tag-finance","tag-xellsmart-bio-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings, Founder H Fund, CE Innovation Capital, Frees Fund, Sequoia Capital China, and Next Capital. The proceeds will be used to fund a pre-clinical study for its iPS-derived cell therapy for neural system diseases, team expansion, and pilot production of its clinical-level iPS-derived cell therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24552\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24552\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-08T12:12:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-31T12:15:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24552#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24552\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies\",\"datePublished\":\"2022-11-08T12:12:00+00:00\",\"dateModified\":\"2025-01-31T12:15:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24552\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cell-therapy\",\"Finance\",\"XellSmart Bio-Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24552#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24552\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24552\",\"name\":\"Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-08T12:12:00+00:00\",\"dateModified\":\"2025-01-31T12:15:16+00:00\",\"description\":\"Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings, Founder H Fund, CE Innovation Capital, Frees Fund, Sequoia Capital China, and Next Capital. The proceeds will be used to fund a pre-clinical study for its iPS-derived cell therapy for neural system diseases, team expansion, and pilot production of its clinical-level iPS-derived cell therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24552#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24552\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24552#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies - Insight, China&#039;s Pharmaceutical Industry","description":"Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings, Founder H Fund, CE Innovation Capital, Frees Fund, Sequoia Capital China, and Next Capital. The proceeds will be used to fund a pre-clinical study for its iPS-derived cell therapy for neural system diseases, team expansion, and pilot production of its clinical-level iPS-derived cell therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24552","og_locale":"en_US","og_type":"article","og_title":"Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24552","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-08T12:12:00+00:00","article_modified_time":"2025-01-31T12:15:16+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24552#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24552"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies","datePublished":"2022-11-08T12:12:00+00:00","dateModified":"2025-01-31T12:15:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24552"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cell-therapy","Finance","XellSmart Bio-Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24552#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24552","url":"https:\/\/flcube.com\/?p=24552","name":"Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-08T12:12:00+00:00","dateModified":"2025-01-31T12:15:16+00:00","description":"Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings, Founder H Fund, CE Innovation Capital, Frees Fund, Sequoia Capital China, and Next Capital. The proceeds will be used to fund a pre-clinical study for its iPS-derived cell therapy for neural system diseases, team expansion, and pilot production of its clinical-level iPS-derived cell therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24552#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24552"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24552#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24552"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24552\/revisions"}],"predecessor-version":[{"id":24553,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24552\/revisions\/24553"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}